- $4.05bn
- $3.45bn
- $1.11bn
- 98
- 50
- 81
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.83 | ||
| PEG Ratio (f) | 0.26 | ||
| EPS Growth (f) | 62.64% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.98 | ||
| Price to Tang. Book | 3.23 | ||
| Price to Free Cashflow | 15.92 | ||
| Price to Sales | 2.54 | ||
| EV to EBITDA | 11.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.1% | ||
| Return on Equity | 17.91% | ||
| Operating Margin | 13.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,094.27 | 1,170.95 | 1,038.76 | 1,173.75 | 1,111.8 | 1,655.88 | 1,522.28 | 4.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +37.18 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Directors
- Richard Pops CHM (59)
- Iain Brown CFO (52)
- Blair Jackson COO (48)
- Craig Hopkinson EVP (53)
- David Gaffin SVP (49)
- Michael Landine SVP (67)
- C.Todd Nichols SVP
- David Anstice LED (72)
- Shane Cooke DRC (58)
- Emily Alva IND (46)
- David Daglio IND
- Wendy Dixon IND (65)
- Richard Gaynor IND (71)
- Cato Laurencin IND (61)
- Brian McKeon IND (58)
- Nancy Snyderman IND (69)
- Frank Wilson IND (63)
- Nancy Wysenski IND (63)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 4th, 2011
- Public Since
- July 16th, 1991
- No. of Shareholders
- 103
- No. of Employees
- 2,280
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 166,881,286
- Address
- Connaught HSE, 1 Burlington Road, DUBLIN, 00000
- Web
- https://www.alkermes.com/
- Phone
- +353 17728000
- Auditors
- PricewaterhouseCoopers LLP
Similar to ALKSV
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 06:02 UTC, shares in Alkermes are trading at $22.64. This share price information is delayed by 15 minutes.
Shares in Alkermes last closed at $22.64 and the price had moved by over the past 365 days. In terms of relative price strength the Alkermes share price has matched the S&P500 Index by over the past year.
The overall consensus recommendation for Alkermes is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Alkermes does not currently pay a dividend.
Alkermes does not currently pay a dividend.
Alkermes does not currently pay a dividend.
To buy shares in Alkermes you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $22.64, shares in Alkermes had a market capitalisation of $4.05bn.
Here are the trading details for Alkermes:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ALKSV
Based on an overall assessment of its quality, value and momentum Alkermes is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alkermes is $33.10. That is 46.2% above the last closing price of $22.64.
Analysts covering Alkermes currently have a consensus Earnings Per Share (EPS) forecast of $1.74 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alkermes. Over the past six months, its share price has matched the S&P500 Index by .
As of the last closing price of $22.64, shares in Alkermes were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alkermes PE ratio based on its reported earnings over the past 12 months is 9.83. The shares last closed at $22.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Alkermes' management team is headed by:
- Richard Pops - CHM
- Iain Brown - CFO
- Blair Jackson - COO
- Craig Hopkinson - EVP
- David Gaffin - SVP
- Michael Landine - SVP
- C.Todd Nichols - SVP
- David Anstice - LED
- Shane Cooke - DRC
- Emily Alva - IND
- David Daglio - IND
- Wendy Dixon - IND
- Richard Gaynor - IND
- Cato Laurencin - IND
- Brian McKeon - IND
- Nancy Snyderman - IND
- Frank Wilson - IND
- Nancy Wysenski - IND